This study is accepting new patients by invitation only
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
- accepting new patients by invitation only
- Start Date
- Completion Date
- Aimmune Therapeutics, Inc.
- Click to request more information about this study.
- Phase 3 research study
- Study Type
- Expecting 950 study participants
- Last Updated